NovoCure
NVCR
362 hedge funds and large institutions have $17.2B invested in NovoCure in 2021 Q2 according to their latest regulatory filings, with 78 funds opening new positions, 125 increasing their positions, 114 reducing their positions, and 43 closing their positions.
81% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 43
73% more capital invested
Capital invested by funds: $9.95B → $17.2B (+$7.28B)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
35% more call options, than puts
Call options by funds: $332M | Put options by funds: $246M
10% more funds holding
Funds holding: 328 → 362 (+34)
1.64% more ownership
Funds ownership: 73.52% → 75.16% (+1.6%)
10% more repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 114
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$624M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$103M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$85M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$69.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$66.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$114M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$79.5M |
| 3 |
Morgan Stanley
New York
|
-$73M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$70.7M |
| 5 |
Two Sigma Investments
New York
|
-$62.3M |
NVCR Hedge Fund Activity: Q2 2021 in Review
362 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q2 2021, worth a combined $17.2B — up 73% from $9.95B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new NVCR positions and 43 closed out — a net gain of 35 holders — while 125 added to existing stakes and 114 trimmed.
The largest buyer was Capital World Investors, adding an estimated $624M. The largest seller was Vanguard Group, cutting an estimated $114M.
- 362 institutional investors held NovoCure (NVCR) as of Q2 2021, up from 328 in Q1 2021.
- Funds reported $17.2B of NovoCure stock for Q2 2021, up 73% quarter-over-quarter.
- 78 funds opened new NovoCure positions in Q2 2021 and 43 closed out, a net change of +35 holders.
- The largest NovoCure buyer in Q2 2021 was Capital World Investors, an estimated $624M added.
- The largest NovoCure seller in Q2 2021 was Vanguard Group, an estimated $114M sold.
Based on aggregated 13F filings for Q2 2021.